Okay, let's tackle this question about Rituximab. The user wants a detailed explanation for an MCQ, so I need to make sure I cover all the required sections.

First, the core concept. Rituximab is a monoclonal antibody. I remember it targets CD20, which is found on B-cells. So the main use is in B-cell malignancies. Also, it's used in autoimmune diseases like rheumatoid arthritis. Wait, but the question is about treatment, so the primary use is in B-cell lymphomas.

Now, the correct answer. The options aren't given, but the user mentioned the correct answer is one of the options. Let's assume the correct answer is B-cell lymphomas. Why? Because rituximab is a chimeric antibody against CD20, depleting B-cells. It's used in non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and some autoimmune conditions. But the main indication is B-cell lymphoma.

Next, the wrong options. Let's think of possible distractors. Maybe options like A. Hodgkin's lymphoma (which is B-cell but less common), C. T-cell lymphoma (since rituximab targets CD20, which isn't on T-cells), D. Myeloma (which is plasma cells, not B-cells). Each of these would be incorrect because they don't involve CD20-expressing B-cells.

Clinical pearl: Rituximab's mechanism is CD20 targeting leading to B-cell depletion. Important to note that it's not effective in T-cell malignancies or plasma cell disorders. Also, infusion reactions are common, so premedication is needed.

Putting it all together, the correct answer is B-cell lymphomas. Need to structure the explanation with the required sections, using bold for key terms and avoiding markdown beyond that. Keep each section concise, under the character limit. Make sure the clinical pearl is high-yield, maybe a mnemonic or key point to remember.

**Core Concept**
Rituximab is a chimeric monoclonal antibody targeting **CD20 antigen** on B-lymphocytes. Its primary use is in **B-cell non-Hodgkin lymphomas (NHL)** and **chronic lymphocytic leukemia (CLL)**, where it induces cell death via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).

**Why the Correct Answer is Right**
Rituximab binds to CD20, a pan-B-cell marker expressed on pre-B and mature B-cells. In NHL (e.g., follicular lymphoma, diffuse large B-cell lymphoma), this binding triggers B-cell depletion. It is also used in autoimmune conditions like rheumatoid arthritis and pemphigus vulgaris, but **its first-line indication remains B-cell malignancies**. The drug’s efficacy is enhanced in combination with chemotherapy (e.g., R-CHOP regimen for NHL).

**Why Each Wrong Option is Incorrect**
**Option A:** *Hodgkin lymphoma* – Incorrect. Hodgkin lymphoma lacks significant CD20 expression; B-cell depletion is ineffective here.
**Option C:** *T-cell lymphoma* – Incorrect. CD20 is absent on T-cells, making

✓ Correct Answer: C. Non-Hodgkinscc lymphoma